This study is the first prospective, real-world data analysis evaluating MammaPrint Index as a predictor of chemotherapy benefit in a propensity-score matched cohort of patients with HR+HER2- early-stage BC across the spectrum of clinical and genomic high and low risk. This evidence concerns the gene ERBB2 and breast cancer.